Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage hodgkin lymphoma in the pre-positron emission tomography era: A Gruppo Italiano Studio Linfomi (GISL) prospective trial

Clinical Lymphoma and Myeloma

Volumn 9, Issue 2, 2009, Pages 138-144

  Iannitto, Emilio ^a   Minardi, Viviana ^a   Gobbi, Paolo ^b   Calvaruso, Giuseppina ^a   Tripodo, Claudio ^a   Marcheselli, Luigi ^c   Luminari, Stefano ^c   Merli, Francesco ^d   Baldini, Luca ^e   Stelitano, Caterina ^f   Callea, Vincenzo ^f   Petrini, Mario ^g   Angrilli, Francesco ^h   Quarta, Giovanni ⁱ   Vallisa, Daniele ^j   Molica, Stefano ^k   Liardo, Eliana ^a   Polimeno, Giuseppe ^l   Brugiatelli, Maura ^m   Federico, Massimo ^c  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d S MARIA NUOVA HOSPITAL   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f Divisione di Ematologia   (Italy)

^g Universitaria Pisana   (Italy)

^h SPIRITO SANTO HOSPITAL   (Italy)

ⁱ Azienda Ospedaliera Perrino   (Italy)

^j Ospedale Civile   (Italy)

^k PUGLIESE CIACCIO HOSPITAL   (Italy)

^l Divisione di Medicina   (Italy)

^m Azienda Ospedaliera Papardo   (Italy)

more..

Author keywords

Bleomycin; Dacarbazine; Doxorubicin; Early restaging; Vinblastine

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE; ABVD PROTOCOL; ANTINEOPLASTIC AGENT;

ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEART INFARCTION; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; INFECTION; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION DOSE; THROMBOCYTOPENIA; ADOLESCENT; AGED; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DACARBAZINE; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; VINBLASTINE; YOUNG ADULT;

EID: 67650669256     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.034     Document Type: Article

References (43)

1. Rosenberg SA. Report of the committee on Hodgkin's disease staging procedures. Cancer Res 1971; 31:1862-3.
2. Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005; 23:6400-8.
3. Diehl V, Thomas RK, Re D, Part II. Hodgkin's lymphoma diagnosis and treatment. Lancet Oncol 2004; 5:19-26.
4. Specht L, Hasenclever D. Prognostic factors. In: Hoppe RT, Mauch PT, Armitage JO, Diehl V, Weiss LM, eds. Hodgkin's disease. Philadelphia: Lippincott Williams & Wilkins; 2007:152-69.
5. Gisselbrecht C, Mounier N, Andre M, et al. How to define intermediate stage in Hodgkin's lymphoma? Eur J Haematol 75:111-114, 2005 (suppl 66)
6. Gobbi PG, Pieresca C, Cavanna L, et al. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL). Haematologica 1996; 81:503-12.
7. Anselmo AP, Cavalieri E, Osti FM, et al. Intermediate stage Hodgkin's disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy. Anticancer Res 2004; 24:4045-50.
8. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of CancerH7 randomized controlled trials. J Clin Oncol 2006; 24:3128-35.
9. Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal vs involved field radiotherapy in early stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22:2835-41.
10. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma study group. J Clin Oncol 2003; 21:3601-8.
11. Ferma C, Eghbali H, Meerwaldt JH, et al. EORTC-GELA H8 Trial. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357:1916-27.
12. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966; 26:1063-83.
13. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630-6.
14. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36:252-9.
15. Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002; 13(suppl 1):79-83.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
17. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: Wiley; 1980.
18. Gobbi PG, Zinzani PL, Broglia C, et al. Comparison of prognostic models in patients with advanced Hodgkin's disease. Cancer 2001; 91:1467-78.
19. Cox DR. Regression models and life table. J Stat Soc 1972; 34:187-220.
20. Mauch P, Terbell D, Weinstein H, et al. Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgical with staged patients in surgical with staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 1988; 6:1576-83.
21. Cimino G, Biti GP, Anselmo AP, et al. MOPP chemotherapy versus extended field radiotherapy in the management pathological stages I-IIA Hodgkin's disease. J Clin Oncol 1989; 7:732-7.
22. Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group Controlled Clinical Trials: 1964-1987. Blood 1989; 73:47-56.
23. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270:1949-55.
24. Henry-Amar M, Hayat M, Meerwaldt JH, et al. Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group. Int J Radiat Oncol Biol Phys 1990; 19:1155-7.
25. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol 1992; 3(suppl 4):117-28.
26. van Leeuwen FE, Swerdlow AJ, Travis LB. Second cancers after treatment of Hodgkin lymphoma. In: Hoppe RT, Mauch PT, Armitage JO, Diehl V, Weiss LM, eds. Hodgkin's disease. Philadelphia: Lippincott Williams & Wilkins; 2007:339-62.
27. Sieber M, Tesch H, Pfistner B, et al. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's Lymphoma: final results of the German Hodgkin's Lymphoma study group trial HD5. J Clin Oncol 2002; 20:476-84.
28. Le Maignan C, Desablens B, Delwail V, et al. Three cycles of Adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood 2004; 103:58-66.
29. Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001; 19:4238-44.
30. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104:3483-9.
31. Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease overview study group. J Clin Oncol 1998; 16:818-29.
32. Levis A, Vitolo U, Ciocca Vasino MA, et al. Predictive value of early response to chemotherapy in high risk stage II and III Hodgkin's disease. Cancer 1997; 60:1713-9.
33. Kuentz M, Reyes F, Brun J, et al. Early response to chemotherapy as prognostic factor in Hodgkin's disease. Cancer 1983; 52:780-5.
34. Bjorkholm M, Axdorph U, Grimfors G, et al. Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial. Ann Oncol 1995; 6:895-9.
35. Carde P, Koscielny S, Frankin J, et al. Early response to chemotherapy: a surrogate for final outcome of Hodgkinn's disease patients that should influence initial treatment length and intensity? Ann Oncol 2002; 13(suppl 1):86-91.
36. Lanman-Parker J, Pacquement H, Leblanc T, et al. Localized Childhood Hodgkin's disease: Response-adapted chemotherapy with Etoposide, Bleomicyn, Vinblastine, and Prednisone before low-dose radiation therapy. Results of the French society of Pediatric Oncology study MDH90. J Clin Oncol 2000; 7:1500-7
37. Hudson MH, Krain M, Link MP, et al. Risk-adapted, combined modality therapy with VAMP/COP and response-based, involved-Field radiation for unfavourable pediatric Hodgkin's disease. J Clin Oncol 2004; 22:4541-50.
38. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91:475-81.
39. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107:52-9.
40. Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006; 17:1296-300.
41. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25:3746-52.
42. Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109:905-9.
43. MacManus MP, Seymour JF, Hicks RJ. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging 2007; 7:10-8.